



ATC codes: **L01DB02**

Indication	Myeloid leukaemia <span>ICD11 code: <b>2C03.1</b></span>
INN	Daunorubicin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection ; 20 mg in vial (as hydrochloride) powder for injection ; 2 mg per mL in vial (as hydrochloride) ; 5 mg per mL in vial (as hydrochloride)
EML status history	First added in 1999 ( <a href="#">TRS 895</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 


Tags

Cancer

Wikipedia

[Daunorubicin](#) 

DrugBank

[Daunorubicin](#) 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.

[Expert Committee report](#) 

